The biotechnology sector, as measured by the XBI ETF, traded down 2.50% in the current session amid a generally negative sentiment for the industry. No single, major catalyst appears to be driving the decline. Rather, it seems to be a continuation of a challenging market environment for clinical-stage biotechnology companies, where investors are showing increased risk aversion. This sentiment is pressuring valuations across the sector in the absence of significant positive news.